Co-Diagnostics (CODX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
4 Sep, 2026Executive summary
Annual Meeting of Stockholders originally scheduled for September 3, 2026, has been adjourned to September 24, 2026, at 9:00 a.m. Mountain Time at the company's Salt Lake City offices.
Supplementary materials were issued to inform shareholders of the new meeting date and location.
Voting matters and shareholder proposals
Shareholders are advised to review the definitive proxy statement and supplemental materials in preparation for the rescheduled Annual Meeting.
Shareholder rights and capital structure
No fee was required for the filing of the definitive additional proxy materials.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Co-Diagnostics
- Regulatory progress amid losses, low cash and substantial going-concern doubt.CODX
Q3 2026 - Convertible debt resale registration creates substantial potential dilution without issuer proceeds.CODXRegistration filing
- Nine proposals seek equity-plan capacity, financing approvals, a lower quorum and reverse-split authority.CODXProxy filing
- Nine proposals seek financing approvals, expanded equity awards, and reverse-split authority up to 1-for-750.CODXProxy filing
- Approval sought for warrant exercise, reverse stock split, and adjournment authority.CODXProxy filing
- ReadyGo collaboration and automation drive blood-based testing, rapid outbreak response, and global expansion.CODXStatus update
- Registering 3.4M shares for resale; up to $5.31M in proceeds possible from warrant exercises.CODXRegistration filing
- Net loss narrowed as regulatory milestones advanced and global commercialization expanded.CODXQ2 2026
- Annual meeting covers director elections, equity plan, pay, auditor, quorum, and adjournment.CODXProxy filing